These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 28988935)

  • 1. Bis-choline tetrathiomolybdate for Wilson's disease.
    Houwen R
    Lancet Gastroenterol Hepatol; 2017 Dec; 2(12):839-840. PubMed ID: 28988935
    [No Abstract]   [Full Text] [Related]  

  • 2. Bis-choline Tetrathiomolybdate as Old Drug in a New Design for Wilson's Disease: Good for Brain and Liver?
    Stremmel W
    Hepatology; 2019 Feb; 69(2):901-903. PubMed ID: 30070374
    [No Abstract]   [Full Text] [Related]  

  • 3. Zinc and tetrathiomolybdate for the treatment of Wilson's disease and the potential efficacy of anticopper therapy in a wide variety of diseases.
    Brewer GJ
    Metallomics; 2009; 1(3):199-206. PubMed ID: 21305118
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrathiomolybdate causes formation of hepatic copper-molybdenum clusters in an animal model of Wilson's disease.
    George GN; Pickering IJ; Harris HH; Gailer J; Klein D; Lichtmannegger J; Summer KH
    J Am Chem Soc; 2003 Feb; 125(7):1704-5. PubMed ID: 12580588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cytopenias secondary to copper depletion complicating ammonium tetrathiomolybdate therapy for Wilson's disease.
    Karunajeewa H; Wall A; Metz J; Grigg A
    Aust N Z J Med; 1998 Apr; 28(2):215-6. PubMed ID: 9612534
    [No Abstract]   [Full Text] [Related]  

  • 6. Practical recommendations and new therapies for Wilson's disease.
    Brewer GJ
    Drugs; 1995 Aug; 50(2):240-9. PubMed ID: 8521757
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interactions of zinc and molybdenum with copper in therapy of Wilson's disease.
    Brewer GJ
    Nutrition; 1995; 11(1 Suppl):114-6. PubMed ID: 7749256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse reaction after tetrathiomolybdate treatment for Wilson's disease: a case report.
    Medici V; Trevisan CP; Bigotto MA; D'Incà R; Martines D; Dal Pont E; Sturniolo GC
    Mov Disord; 2006 Nov; 21(11):2030-2. PubMed ID: 16991142
    [No Abstract]   [Full Text] [Related]  

  • 9. Analyzing the Therapeutic Efficacy of Bis-Choline-Tetrathiomolybdate in the
    Kim P; Zhang CC; Thoröe-Boveleth S; Buhl EM; Weiskirchen S; Stremmel W; Merle U; Weiskirchen R
    Biomedicines; 2021 Dec; 9(12):. PubMed ID: 34944677
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tracing copper-thiomolybdate complexes in a prospective treatment for Wilson's disease.
    Zhang L; Lichtmannegger J; Summer KH; Webb S; Pickering IJ; George GN
    Biochemistry; 2009 Feb; 48(5):891-7. PubMed ID: 19146437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Wilson's disease].
    Kovacević I; Zekan M
    Acta Med Croatica; 2003; 57(3):227-35. PubMed ID: 14582469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Does molybdenum play a role in Wilson's disease?].
    Galli A
    Ann Biol Clin (Paris); 1968; 26(7):975-8. PubMed ID: 5727320
    [No Abstract]   [Full Text] [Related]  

  • 13. Pathophysiology and treatment of Wilson's disease.
    Tankanow RM
    Clin Pharm; 1991 Nov; 10(11):839-49. PubMed ID: 1794220
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depression in hepatolenticular degeneration (Wilson's disease).
    Walter G; Lyndon B
    Aust N Z J Psychiatry; 1997 Dec; 31(6):880-2. PubMed ID: 9483264
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regression of Kayser-Fleischer rings during oral zinc therapy: correlation with systemic manifestations of Wilson's disease.
    Esmaeli B; Burnstine MA; Martonyi CL; Sugar A; Johnson V; Brewer GJ
    Cornea; 1996 Nov; 15(6):582-8. PubMed ID: 8899270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurologically presenting Wilson's disease: epidemiology, pathophysiology and treatment.
    Brewer GJ
    CNS Drugs; 2005; 19(3):185-92. PubMed ID: 15740174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical considerations for an effective medical therapy in Wilson's disease.
    Weiss KH; Stremmel W
    Ann N Y Acad Sci; 2014 May; 1315():81-5. PubMed ID: 24754532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Wilson's disease].
    Cramarossa L; D'Angelo D; D'Ascanio I; Ferri GB; Piane E
    Recenti Prog Med; 1992 May; 83(5):255-61. PubMed ID: 1439104
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A critical evaluation of copper metabolism in Indian Wilson's disease children with special reference to their phenotypes and relatives.
    Prasad R; Kaur G; Walia BN
    Biol Trace Elem Res; 1998 Nov; 65(2):153-65. PubMed ID: 9881519
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Studies of cholecystokinin-stimulated biliary secretions reveal a high molecular weight copper-binding substance in normal subjects that is absent in patients with Wilson's disease.
    Iyengar V; Brewer GJ; Dick RD; Chung OY
    J Lab Clin Med; 1988 Mar; 111(3):267-74. PubMed ID: 3125292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.